3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
6
Gynecologic
6
Gastrointestinal
5
Breast
3
Tumor-Agnostic
2
Thoracic
2
Sarcoma
2
Plasma cell
1
Genitourinary
1
Endocrine
1
Dermatologic
1
Conditions
Neoplasms
2
Interventions
pembrolizumab
26
Specimen Handling
22
Biopsy
22
Magnetic Resonance Spectroscopy
20
Paclitaxel
12
Carboplatin
10
Blood Specimen Collection
10
Bevacizumab
10
atezolizumab
9
Standard of Care
9
Nivolumab
9
Cisplatin
8
Radiosurgery
7
Pemetrexed
7
Gemcitabine
6
Cyclophosphamide
6
Capecitabine
6
trastuzumab deruxtecan
5
durvalumab
5
X-Rays
5
Taxes
5
Surveys and Questionnaires
5
Irinotecan
5
Fluorouracil
5
olaparib
4
niraparib
4
cabozantinib
4
Radiotherapy
4
Oxaliplatin
4
Leucovorin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
dostarlimab
×
Tumor-Agnostic
×
90 days
×
Clear all
NCT06551142
2026-05-22
PanTumor-101
GlaxoSmithKline
Phase 1
Recruiting
845 enrolled
NCT06796907
2026-05-22
BEHOLD-2
GlaxoSmithKline
Phase 1/2
Recruiting
305 enrolled